A Phase II, Multi-center, Open-label, Single-arm Study of the Efficacy and Safety of Oral LDE225 in Patients With Hh-pathway Activated Relapsed Medulloblastoma
Phase of Trial: Phase II
Latest Information Update: 04 Aug 2017
At a glance
- Drugs Sonidegib (Primary) ; Temozolomide
- Indications Medulloblastoma
- Focus Therapeutic Use
- Acronyms CLIMB
- Sponsors Novartis Pharmaceuticals
- 16 May 2017 Status changed from active, no longer recruiting to completed.
- 25 Jan 2017 This trial has been completed in Italy (End date:2016-10-05) as per European Clinical Trials Database record.
- 18 Jan 2017 This trial has been completed in Sweden (End date:2016-10-05) as per European Clinical Trials Database record.